Boston Scientific Corporation
BSX · NYSE
Next quarter
Reports Oct 28, 2026.
Consensus is $0.80 EPS for Sep 2026 across 8 estimates, ranging $0.79 to $0.81.
BSX Jun 2026
- 3.61%
- -0.09%
- $0.83
- $0.86
- —
- $5.44B
Reported results
- $5.44B
- 70.71%
- $1.18B
- 21.65%
- $905.00M
- $0.61
Highlights
- Second-quarter 2026 revenue was $5.44B, compared with $5.06B in the second quarter of 2025 and $5.20B in the first quarter of 2026.
- Second-quarter 2026 net income was $0.91B, compared with $0.80B in the year-earlier quarter and $1.34B in the first quarter of 2026.
- No intangible asset impairment charges were recorded in the second quarter or first six months of 2026, versus $46 million in both periods of 2025.
- Total hedging-instrument notional outstanding was $15.382B at June 30, 2026, compared with $13.723B at December 31, 2025.
- Boston Scientific had no amounts outstanding under its $3.000B revolving credit agreement, $2.000B 364-day revolving credit agreement, or $6.000B term loan agreement at June 30, 2026; its actual leverage ratio was 2.02 times against a 4.00-times permitted maximum.
Analysis
No consensus figures are available, so the quarter cannot be judged against an external earnings expectation. Revenue was $5.44B, up from $5.06B in the year-earlier second quarter and from $5.20B in the first quarter, while net income was $0.91B, above $0.80B a year earlier but below $1.34B in the preceding quarter. The supplied filing excerpt does not provide reportable-segment revenue, segment operating results, operating margins, or management’s explanation of the quarter’s revenue and earnings drivers. It therefore does not support identifying which businesses carried or dragged performance, or explaining any margin movement. The absence of intangible asset impairment charges in 2026 helped distinguish the period from 2025, when Boston Scientific recorded $46 million in the second quarter and first six months. Currency effects were mixed: the company reported a $15 million net currency exchange loss in the quarter, compared with approximately zero in the year-earlier period.
Guidance
No forward revenue, earnings, margin, subscriber, unit, or capital-expenditure guidance was provided in the supplied material. The filing instead describes financing capacity and covenant expectations. Boston Scientific entered into a $3.000B revolving credit agreement, a $2.000B 364-day revolving credit agreement, and a $6.000B delayed-draw term loan agreement, with no amounts outstanding under any of them at June 30, 2026. Management stated that the company believes it can comply with its financial covenant for the next 12 months. The actual leverage ratio was 2.02 times versus a 4.00-times permitted maximum at June 30, 2026.
What drove it
- Revenue growth — Second-quarter revenue was $5.44B, compared with $5.06B in the second quarter of 2025.
- Net income — Second-quarter net income was $0.91B, compared with $0.80B in the year-earlier quarter and $1.34B in the first quarter of 2026.
- Impairment charges — No intangible asset impairment charges were recorded in the second quarter or first six months of 2026, versus $46 million in both periods of 2025.
- Currency exposure — The second-quarter net currency exchange loss was $15 million, compared with $0 million in the second quarter of 2025.
- Balance-sheet capacity — The company had no amounts outstanding under its $3.000B revolving credit agreement, $2.000B 364-day revolving credit agreement, or $6.000B term loan agreement.
Watch items
- The supplied material does not provide segment results, margins, or operating explanations, limiting visibility into the sources and durability of revenue and earnings performance.
- Net income fell from $1.34B in the first quarter of 2026 to $0.91B in the second quarter, despite revenue increasing from $5.20B to $5.44B.
- The company recorded a $15 million net currency exchange loss in the second quarter of 2026, compared with approximately zero in the year-earlier quarter.
- Total hedging-instrument notional outstanding increased to $15.382B from $13.723B at December 31, 2025, highlighting continued foreign-exchange exposure.
